Indivior/$INDV
Indivior falls after announcing a private offering of $400M convertible senior notes due 2031.
6 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Indivior
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Ticker
$INDV
Sector
Primary listing
Employees
833
Headquarters
Website
Indivior Metrics
BasicAdvanced
$4.1B
20.02
$1.64
1.19
-
Price and volume
Market cap
$4.1B
Beta
1.19
52-week high
$36.03
52-week low
$30.33
Average daily volume
2M
Financial strength
Current ratio
0.713
Quick ratio
0.492
Long term debt to equity
-318.367
Total debt to equity
-358.163
Interest coverage (TTM)
8.60%
Profitability
EBITDA (TTM)
298
Gross margin (TTM)
81.28%
Net profit margin (TTM)
16.95%
Operating margin (TTM)
23.24%
Effective tax rate (TTM)
12.13%
Revenue per employee (TTM)
$1,490,000
Management effectiveness
Return on assets (TTM)
14.30%
Return on equity (TTM)
-96.55%
Valuation
Price to earnings (TTM)
20.018
Price to revenue (TTM)
3.312
Price to book
-41.88
Price to tangible book (TTM)
-41.04
Price to free cash flow (TTM)
-43.657
Free cash flow yield (TTM)
-2.29%
Free cash flow per share (TTM)
-0.752
Growth
Revenue change (TTM)
4.29%
Earnings per share change (TTM)
3,180.00%
3-year revenue growth (CAGR)
11.20%
10-year revenue growth (CAGR)
2.02%
3-year earnings per share growth (CAGR)
72.41%
10-year earnings per share growth (CAGR)
0.57%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Indivior stock?
Indivior (INDV) has a market cap of $4.1B as of March 13, 2026.
What is the P/E ratio for Indivior stock?
The price to earnings (P/E) ratio for Indivior (INDV) stock is 20.02 as of March 13, 2026.
Does Indivior stock pay dividends?
No, Indivior (INDV) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Indivior dividend payment date?
Indivior (INDV) stock does not pay dividends to its shareholders.
What is the beta indicator for Indivior?
Indivior (INDV) has a beta rating of 1.19. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.